RecruitingPhase 1

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

United States70 participantsStarted 2026-03-31

Plain-language summary

The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has not been FDA approved. Its use in this study is investigational.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy control cohort:
✓. Able to consistently hold breath for 10-12 seconds
✓. No history of any pulmonary disorders (i.e., asthma, COPD, lung cancer, etc.)
✓. Able to undergo MRI examination
✓. At least 18 years of age
✓. Lung cancer patient cohort:
✓. Biopsy proven diagnosis of lung cancer
✓. Receiving photon- or proton-based external beam radiotherapy as a part of treatment

Exclusion criteria

✕. Patients unable to follow up at MD Anderson for routine clinical care
✕. Inability or unwillingness to give informed consent
✕. Relapsed disease or life expectancy less than 6 months at time of enrollment
✕. Severe claustrophobia precluding MRI imaging active pulmonary infection
✕. Pregnant women
✕. Under 18 years of age

What they're measuring

Safety and Adverse Events (AEs)

Timeframe: Through study completion; an average of 1 year

Trial details

NCT IDNCT06909201

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-09-01

Contact for this trial

Joshua Niedzielski, PHD

(713) 745-8946 jsniedzielski@mdanderson.org

View on ClinicalTrials.gov More Lung Cancer trials